A method for detecting the content of recombinant humanized collagen in a sample

Through high performance liquid chromatography and appropriate sample pretreatment methods, the sensitivity and accuracy of the detection of low-concentration collagen in dressings in the prior art is solved, and the rapid and accurate collagen content detection is achieved, which meets the detection Economical and precision requirements.

CN118348154BActive Publication Date: 2024-11-15SHANXI JINBO BIO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410516963.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-26
Publication Date
2024-11-15
Estimated Expiration
2044-04-26

AI Technical Summary

Technical Problem

The existing detection methods have low detection sensitivity, poor accuracy, and errors for dressings containing recombinant humanized collagen and sodium hyaluronate, which fail to meet the needs of fast, accurate and economical testing.

Method used

The dressing samples were treated by high performance liquid chromatography, through the preparation of reference and test samples and liquid chromatography detection, combined with dilution and enzymatic method, and the dressing samples were treated with octadecylsilane-bonded silica gel chromatography column and gradient elution. Methods: detect the content of recombinant humanized collagen.

Benefits of technology

The rapid, accurate and precise detection of the recombinant humanized collagen content in the dressing is achieved. The detection limit and quantitative limit reach 0.05mg/ml and 0.1mg/ml respectively, with good repeatability and suitable for detecting collagen in dressing samples. Protein content.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118348154B_ABST
    Figure CN118348154B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biological detection technology, and specifically relates to a method for detecting the content of recombinant humanized collagen in a sample, wherein the sample contains recombinant humanized collagen and sodium hyaluronate; the method comprises the following steps: preparation of a reference solution, preparation of a test solution, liquid chromatography detection and data analysis. The detection method provided by the present invention has strong specificity, and when the content of recombinant humanized collagen is within a certain range, its concentration has a good linear relationship with the chromatographic peak area, high accuracy, good repeatability, and the detection limit and quantitative limit can reach 0.05 mg / ml and 0.1 mg / ml respectively.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biological detection technology, and specifically relates to a method for detecting the content of recombinant humanized collagen in a sample, and more specifically relates to a method for detecting the content of recombinant humanized collagen in a sample containing hyaluronic acid or its salt (such as sodium salt). Background Art

[0002] Collagen is a biopolymer and the most important component of the extracellular matrix. In the outer matrix of human skin cells, collagen accounts for 80% and hyaluronic acid accounts for 20%. At the same time, collagen is the largest and most abundant protein in the human body, and its unique triple helix structure makes its properties very stable. In addition, collagen has biocompatibility that other polymer materials do not have, low immunogenicity, elasticity to support cells and degradability, and is widely used in beauty, medical, food and other fields.

[0003] In the past production practice, a large amount of collagen came from animals (such as pigs, cattle, etc.), but the antigenicity of animal proteins has always been a difficult problem to overcome. In recent years, with the continuous development of basic theories, technical means and clinical medical exploration research such as gene recombination and proteomics, many scholars have conducted extensive research on the expression of recombinant (human-like) collagen.

[0004] Recombinant humanized collagen is a full-length or partial amino acid sequence fragment encoded by a specific type of human collagen gene prepared by DNA recombination technology, or a combination of functional human collagen fragments. It is a homologous substance to human collagen, has higher biological activity than human collagen, is highly compatible with the human body, and will not cause adverse reactions caused by non-human components, thus playing a physiological role in various tissues of the human body.

[0005] Medical wound dressings containing recombinant humanized collagen and sodium hyaluronate are common medical devices and have been widely used in the medical field. At present, the main method for detecting the collagen content in dressings is the Kjeldahl method, but this method determines the total organic nitrogen, not just the protein nitrogen, and the experimental time is too long, the accuracy is poor, and the reagents used are corrosive. Especially for dressings containing sodium hyaluronate, the content of sodium hyaluronate interferes with the detection of protein (the N-acetylglucosamine fragment in the hyaluronic acid molecule also contains nitrogen), and the error of low-concentration protein determination is large. At present, there is no relevant literature reporting on the detection of collagen content in this type of product. It is very necessary to develop a new method for detecting collagen content. Summary of the invention

[0006] Problem that the invention aims to solve

[0007] Although there are methods such as Kjeldahl nitrogen determination for detecting protein content in dressings containing recombinant humanized collagen and sodium hyaluronate, the sensitivity and repeatability of the method for detecting low concentrations of recombinant humanized collagen in dressings with complex ingredients are low, so from the perspectives of accuracy, simplicity and economy of detection, there is still room for development of methods for detecting the content of recombinant humanized collagen. In this regard, the present invention aims to provide a method with high sensitivity that can quickly and accurately detect the content of recombinant humanized collagen in dressing samples.

[0008] Solutions for solving problems

[0009] [1] A method for detecting the content of recombinant humanized collagen in a sample, wherein:

[0010] The sample contains recombinant humanized collagen and sodium hyaluronate;

[0011] The method comprises the following steps: preparation of reference solution, preparation of test solution, liquid chromatography detection and data analysis.

[0012] [2] The method according to [1], wherein:

[0013] The data analysis includes calculating the concentration of the recombinant humanized collagen in the test solution by using an external standard method, and then obtaining the content of the recombinant humanized collagen in the sample.

[0014] [3] The method according to [1] or [2], wherein:

[0015] When the content of recombinant humanized collagen in the sample is greater than or equal to 0.5 mg / mL, the preparation of the test solution includes the steps shown in the following dilution method:

[0016] Dilution method: accurately weigh the sample, place it in a container, add solvent to dilute it 3 to 4 times; preferably, the solvent is purified water or PBS solution.

[0017] [4] The method according to [3], wherein:

[0018] The preparation of the reference solution comprises the following steps: accurately weighing the recombinant humanized collagen reference, placing it in a container, and adding a solvent to dissolve it; preferably, the solvent is purified water or PBS solution.

[0019] [5] The method according to [1] or [2], wherein:

[0020] When the content of recombinant humanized collagen in the sample is less than or equal to 1.0 mg / mL, the preparation of the test solution includes the steps shown in the following enzymatic hydrolysis method:

[0021] Enzymatic hydrolysis method: Accurately weigh the sample, place it in a container, add hyaluronidase, mix well, and place it in an environment of 4-6℃ for enzymatic hydrolysis reaction.

[0022] [6] The method according to [5], wherein:

[0023] The preparation of the reference solution comprises the following steps: accurately weighing a dressing reference, placing it in a container, adding hyaluronidase, mixing, and placing it in an environment of 4 to 6° C. for enzymatic hydrolysis to obtain the dressing reference solution; wherein the dressing reference solution comprises the recombinant humanized collagen and sodium hyaluronate.

[0024] [7] The method according to [5] or [6], wherein:

[0025] The mass ratio of the amount of the hyaluronidase to the sample is (1-900) IU: 1 g, and the time of the enzymatic reaction is 5 min to 24 h.

[0026] [8] The method according to any one of [1] to [7], wherein

[0027] The conditions used in the liquid chromatography detection include:

[0028] The chromatographic column is an octadecylsilane bonded silica gel chromatographic column;

[0029] The mobile phase is a water-acetonitrile binary mobile phase system; preferably, the water-acetonitrile binary mobile phase system contains an organic acid, preferably trifluoroacetic acid; more preferably, in the water-acetonitrile binary mobile phase system, mobile phase A is a trifluoroacetic acid aqueous solution with a trifluoroacetic acid content of 0.1% v / v; mobile phase B is a trifluoroacetic acid acetonitrile solution with a trifluoroacetic acid content of 0.1% v / v;

[0030] The elution method was gradient elution.

[0031] [9] The method according to [8], wherein:

[0032] The procedure of the gradient elution is as follows:

[0033] Time / min Mobile phase A / % v / v Mobile phase B / % v / v 0→3 95 5 3→6 95→88 5→12 6→8 88→87 12→13 8→9 87→85 13→15 9→14 85→80 15→20 14→20 80→75 20→25 20→22 75→74.5 25→25.5 22→27 74.5→70 25.5→30 27→29 70→95 30→5 29→30 95 5

[0034]

[10] The method according to [8] or [9], wherein:

[0035] The conditions adopted by the liquid chromatography detection also include:

[0036] Flow rate 0.5-1.3 mL / min;

[0037] Column temperature is 27-37°C;

[0038] The detection wavelength is 200-230nm;

[0039] The injection volume was 8-22 μL.

[0040] Effects of the Invention

[0041] The present invention provides a method for quantitatively detecting the content of recombinant humanized collagen in dressing samples based on high performance liquid chromatography. The method has strong specificity. When the content of recombinant humanized collagen is within a certain range, its concentration has a good linear relationship with the chromatographic peak area, high accuracy, good repeatability, and the detection limit and quantitative limit can reach 0.05 mg / ml and 0.1 mg / ml respectively. In general, the detection method provided by the present invention is fast, accurate, precise and has good repeatability, and can be used to detect the content of recombinant humanized collagen in dressing samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 : Specificity measurement spectrum in Example 1; wherein a is the chromatogram of the reference solution, b is the chromatogram of the test solution, and c is the chromatogram of the blank solution.

[0043] Figure 2 : Linear relationship diagram between concentration and peak area of ​​reference substance solution in Example 1.

[0044] Figure 3 : Specificity measurement spectrum in Example 2; wherein, a is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 1.0 mg / ml, b is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 0.5 mg / ml, c is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 0.25 mg / ml, d is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 0.125 mg / ml, e is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 0.1 mg / ml, f is a chromatogram of the reference solution prepared with a dressing having a protein concentration of 0.05 mg / ml, and g is a chromatogram of the blank solution.

[0045] Figure 4 : Linear relationship diagram of the concentration and peak area of ​​the reference substance solution in Example 2.

[0046] Figure 5 : Chromatograms obtained under different pretreatment methods in Example 3; wherein a is a chromatogram of protein heated with alkali, b is a chromatogram of protein heated with alkali, and c is a chromatogram of protein without any treatment.

[0047] Figure 6 : Chromatographic changes of samples before and after protein hydrolysis using 90 μL of Bloomage Biotechnology hyaluronidase in Example 3.

[0048] Figure 7 : Chromatographic changes of samples before and after protein hydrolysis using 50 μL, 20 μL, and 10 μL of Bloomage Biotechnology hyaluronidase in Example 3.

[0049] Figure 8 : Chromatographic changes of samples in Example 3 after enzymatic hydrolysis for 2h using 50μL, 100μL, 200μL, and 250μL of Merck hyaluronidase.

[0050] Fig. 9 : Chromatographic changes of samples in Example 3 after enzymatic hydrolysis for 12 hours using 100 μL, 200 μL, and 250 μL of Merck hyaluronidase.

[0051] Fig.10 : Chromatographic changes of samples in Example 3 after enzymatic hydrolysis for 24 hours using 100 μL, 200 μL, and 250 μL of Merck hyaluronidase.

[0052] Fig.11 : UV spectrum of the sample in Example 3 within the range of 200-800nm.

[0053] Fig.12 : Sample chromatograms under different mobile phases in Example 3.

[0054] Fig.13 : Chromatograms of samples under different column temperatures and flow rates in Example 3.

[0055] Fig.14A : Chromatograms of two groups of parallel samples of 0.1 mg / ml using enzymatic pretreatment of dressings in Example 4.

[0056] Fig. 14B : Chromatograms of two groups of parallel samples of 0.5 mg / ml using enzymatic pretreatment of dressings in Example 4.

[0057] Fig. 14C : Chromatograms of two groups of parallel samples of 1.0 mg / ml using the dilution method for pre-treatment of dressings in Example 4. DETAILED DESCRIPTION

[0058] The embodiments of the present invention are described below, but the present invention is not limited thereto. The present invention is not limited to the various structures described below, and various changes can be made within the scope of the present invention, and the embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments and examples are also included in the technical scope of the present invention.

[0059] I. Definition of Terms

[0060] In the present invention, a numerical range expressed using “a value A to a value B”, “a value A - a value B”, “above a value A” or below a value A means a range including the endpoints A and B.

[0061] In the present invention, the term "a" or "an" or "the" may mean "one", and may also mean "one or more", "at least one" and "one or more than one".

[0062] In the present invention, the terms "comprising", "having", "including" or "containing" may mean inclusive or open-ended, and do not exclude additional, uncited elements or method steps. At the same time, "comprising", "having", "including" or "containing" may also mean closed, excluding additional, uncited elements or method steps.

[0063] In the present invention, the term "recombinant humanized collagen" refers to the full-length or partial amino acid sequence fragment encoded by the gene of a specific type of human collagen prepared by DNA recombination technology, or a combination of functional fragments of human collagen. Further, the term "recombinant type III humanized collagen" refers to the recombinant collagen encoded by the collagen COL3A1 gene or a partial gene prepared by DNA recombination technology.

[0064] In the present invention, the terms "sodium hyaluronate enzyme" and "hyaluronidase" have the same meaning, and refer to an enzyme that can hydrolyze hyaluronic acid or hyaluronate (such as sodium hyaluronate).

[0065] In the present invention, the term "dressing" refers to various medical materials used to cover wounds / wound surfaces, such as non-chronic wounds (superficial wounds, small wounds, abrasions, cut wounds) and surrounding skin care, as well as to prevent scar formation of plastic surgery incisions. In some embodiments, the dressing of the present invention comprises recombinant humanized collagen, sodium hyaluronate and phosphate buffer. In some embodiments, the dressing of the present invention consists of recombinant humanized collagen, sodium hyaluronate and phosphate buffer.

[0066] II. Method for detecting the content of recombinant humanized collagen in a sample

[0067] In some embodiments, the method provided by the present invention for detecting the content of recombinant humanized collagen in a sample comprises the following steps: preparation of a reference solution, preparation of a test solution, liquid chromatography detection and data analysis.

[0068] The present invention provides a method for detecting the content of recombinant humanized collagen in a sample. The method is based on high performance liquid chromatography and can efficiently detect the content of recombinant humanized collagen in a dressing through appropriate sample pretreatment. The method has the advantages of being fast, accurate, precise and repeatable.

[0069] i.Sample

[0070] The sample targeted by the detection method provided by the present invention is a dressing sample containing recombinant humanized collagen and sodium hyaluronate.

[0071] In some embodiments, the sample comprises recombinant humanized collagen, sodium hyaluronate and phosphate buffer. In some specific embodiments, the sample consists of recombinant humanized collagen, sodium hyaluronate and phosphate buffer.

[0072] In some embodiments, the recombinant humanized collagen comprises recombinant humanized type III collagen.

[0073] In some preferred embodiments, the recombinant humanized collagen is recombinant humanized type III collagen.

[0074] In some embodiments, the recombinant humanized type III collagen includes the recombinant humanized type III collagen in ZL201811438582.6.

[0075] In some preferred embodiments, the recombinant humanized type III collagen is the recombinant humanized type III collagen in ZL201811438582.6.

[0076] In some more preferred embodiments, the recombinant humanized type III collagen comprises:

[0077] a) the amino acid sequence of SEQ ID NO.1;

[0078] b) an amino acid sequence having 90%, 92%, 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO.1, which retains the cell adhesion effect of the amino acid sequence of SEQ ID NO.1;

[0079] c) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of SEQ ID NO.1, which retains the cell adhesion effect of the amino acid sequence of SEQ ID NO.1; or

[0080] d) an amino acid sequence encoded by a nucleotide sequence, which hybridizes with a polynucleotide sequence encoding the amino acid sequence of SEQ ID NO.1 under stringent conditions, and the amino acid sequence retains the cell adhesion effect of the amino acid sequence of SEQ ID NO.1, wherein the stringent conditions are medium stringent conditions, medium-high stringent conditions, high stringent conditions or very high stringent conditions.

[0081] In some specific embodiments, the sample consists of recombinant humanized type III collagen with an amino acid sequence as shown in SEQ ID NO.1, sodium hyaluronate and phosphate buffer.

[0082] ii. Preparation of test solution and reference solution

[0083] In order to more accurately detect the content of recombinant humanized collagen in a sample, the present invention provides different sample pretreatment methods according to different recombinant humanized collagen contents provided in the sample information.

[0084] In some embodiments, when the content of recombinant humanized collagen in the sample is greater than or equal to 0.5 mg / mL, the preparation of the test solution includes the steps shown in the following dilution method:

[0085] Dilution method: accurately weigh the sample, place it in a container, and add a solvent to dilute it 3 to 4 times; preferably, the solvent is purified water or PBS solution; more preferably, the solvent is purified water.

[0086] In the dilution method, the purpose of diluting 3 to 4 times is to reduce the viscosity of the sample for filtration and liquid chromatography detection. In some embodiments, in order to avoid the content of recombinant humanized collagen in the diluted sample being too low and below the detection limit or quantitative limit, or causing a large error, the content of recombinant humanized collagen in the diluted sample is greater than or equal to 0.125 mg / mL.

[0087] Furthermore, when the test solution is prepared by the dilution method, the preparation of the reference solution includes the following steps: accurately weighing the recombinant humanized collagen reference, placing it in a container, and adding a solvent to dissolve it; preferably, the solvent is purified water or PBS solution; more preferably, the solvent is purified water.

[0088] In some embodiments, the recombinant humanized collagen reference substance is recombinant humanized collagen lyophilized; the present invention does not particularly limit the specific preparation method of the recombinant humanized collagen lyophilized, for example, the recombinant humanized collagen can be produced by chemical synthesis, microbial fermentation and the like, and then freeze-dried.

[0089] In some embodiments, when the content of recombinant humanized collagen in the sample is less than or equal to 1.0 mg / mL, the preparation of the test solution includes the steps shown in the following enzymatic hydrolysis method:

[0090] Enzymatic hydrolysis method: accurately weigh the sample, place it in a container, add hyaluronidase, mix well, and place it in an environment of 4 to 6°C for enzymatic hydrolysis reaction; the preferred enzymatic hydrolysis environment temperature is 5°C.

[0091] Furthermore, when the test solution is prepared by enzymatic hydrolysis, the preparation of the reference solution includes the following steps: accurately weighing the dressing reference, placing it in a container, adding hyaluronidase, mixing, and placing it in an environment of 4 to 6°C for enzymatic hydrolysis reaction; the preferred enzymatic hydrolysis environment temperature is 5°C; wherein the dressing reference contains the recombinant humanized collagen and sodium hyaluronate; preferably, the dressing reference contains the recombinant humanized collagen, sodium hyaluronate and phosphate buffer; more preferably, the dressing reference consists of the recombinant humanized collagen, sodium hyaluronate and phosphate buffer.

[0092] In the enzymatic hydrolysis method, the purpose of adding hyaluronidase is to reduce the viscosity of the sample or dressing control to facilitate filtration and liquid chromatography detection.

[0093] In some embodiments, in order to avoid the effect of the enzymatic hydrolysis process on the recombinant humanized collagen and thus affect the detection results, the mass ratio of the amount of hyaluronidase used to the sample is (1-900) IU: 1 g, and the enzymatic hydrolysis reaction time is 5 min to 24 h.

[0094] The present invention does not particularly limit the dosage of hyaluronidase and the enzymolysis time, which can be selected according to the activity of the hyaluronidase selected.

[0095] In some specific embodiments, the hyaluronidase is 10000 IU / ml hyaluronidase from Huaxi Biotechnology, the mass ratio of the hyaluronidase to the sample is (100-900) IU:1g, preferably (200-600) IU:1g, and the enzymatic reaction time is 5min-10h, preferably 5min-2h.

[0096] In some specific embodiments, the hyaluronidase is 100 IU / ml hyaluronidase from Merck, the mass ratio of the hyaluronidase to the sample is (1-5) IU:1g, preferably (2-4) IU:1g, more preferably 4 IU:1g, and the enzymatic reaction time is 5h-24h, preferably 12h-20h, more preferably 12h.

[0097] In some specific embodiments, in the preparation of the test solution and the preparation of the reference solution, the weighed amount of the sample is equal to the weighed amount of the reference, and the amount of the test solution finally obtained is equal to the amount of the reference solution.

[0098] In some specific embodiments, after the preparation of the test solution and the reference solution, they need to be filtered before liquid chromatography detection to avoid impurities from adversely affecting liquid chromatography detection.

[0099] iii. Liquid chromatography detection

[0100] In some embodiments, the chromatographic column used for the liquid chromatography detection is an octadecylsilane bonded silica gel chromatographic column; the preferred specification is Agilent Eclipse XDB-C18, 4.6×150nm, 5μm.

[0101] In some embodiments, the mobile phase used in the liquid chromatography detection is a water-acetonitrile binary mobile phase system; preferably, the water-acetonitrile binary mobile phase system contains an organic acid, preferably trifluoroacetic acid; more preferably, in the water-acetonitrile binary mobile phase system, mobile phase A is a trifluoroacetic acid aqueous solution with a trifluoroacetic acid content of 0.1% v / v; mobile phase B is a trifluoroacetic acid acetonitrile solution with a trifluoroacetic acid content of 0.1% v / v;

[0102] In some embodiments, the elution method used in the liquid chromatography detection is gradient elution.

[0103] In some embodiments, the gradient elution procedure is as follows:

[0104] Time / min Mobile phase A / % v / v Mobile phase B / % v / v 0→3 95 5 3→6 95→88 5→12 6→8 88→87 12→13 8→9 87→85 13→15 9→14 85→80 15→20 14→20 80→75 20→25 20→22 75→74.5 25→25.5 22→27 74.5→70 25.5→30 27→29 70→95 30→5 29→30 95 5

[0105] In some embodiments, the flow rate used in the liquid chromatography detection is 0.5-1.3 mL / min, for example, 0.5 mL / min, 0.6 mL / min, 0.7 mL / min, 0.8 mL / min, 0.9 mL / min, 1.0 mL / min, 1.1 mL / min, 1.2 mL / min or 1.3 mL / min, etc., preferably 0.6-1.0 mL / min, and more preferably 1.0 mL / min.

[0106] In some embodiments, the column temperature used for liquid chromatography detection is 27-37°C, for example, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C or 37°C, etc., preferably 30-35°C, more preferably 30°C.

[0107] In some embodiments, the detection wavelength used in the liquid chromatography detection is 200-230 nm, for example, 203 nm, 207 nm, 210 nm, 214 nm, 217 nm, 220 nm, 223 nm, 227 nm or 230 nm, etc., preferably 210 to 220 nm, and more preferably 214 nm.

[0108] In some embodiments, the injection volume used for the liquid chromatography detection is 8-22 μL, for example, 9 μL, 10 μL, 11 μL, 12 μL, 13 μL, 14 μL, 15 μL, 16 μL, 17 μL, 18 μL, 19 μL, 20 μL, 21 μL or 22 μL, etc.; preferably 10-20 μL.

[0109] iv. Data analysis

[0110] In some embodiments, the data analysis includes calculating the concentration of the recombinant humanized collagen in the test solution using an external standard method, thereby obtaining the content of the recombinant humanized collagen in the sample.

[0111] III. Amino Acid Sequences of Proteins Used in Examples

[0112] The amino acid sequence of recombinant humanized type III collagen (SEQ ID NO.1): GERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAG ERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGER GAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGA PGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAPGERGAPGFRGPAGPNGIPGEKGPAGERGAP.

[0113] Example

[0114] The embodiments of the present invention will be described in detail below in conjunction with examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out under normal conditions or conditions recommended by the manufacturer. Unless otherwise specified, the materials or instruments used are all commercially available conventional products.

[0115] Example 1

[0116] 1. Instrument

[0117] Agilent 1260 high performance liquid chromatograph (UV detector), BCE3202-1CCN electronic balance (Sartorius).

[0118] 2. Reagents and Materials

[0119] Trifluoroacetic acid (Merck, TFA suitable for HPLC, ≥99.0%), acetonitrile (Merck, suitable for HPLC, gradient grade, ≥99.9%), water (Wahaha), dressing 1 (Shanxi Jinbo Biopharmaceutical Co., Ltd.), recombinant type III humanized collagen freeze-dried (Shanxi Jinbo Biopharmaceutical Co., Ltd.);

[0120] Dressing 1 formula: recombinant humanized type III collagen (concentration of 1.0 mg / ml), supplemented with sodium hyaluronate and PBS buffer solution.

[0121] 3. Solution Preparation

[0122] Preparation of reference solution: Take lyophilized recombinant type III humanized collagen, dissolve and dilute to 1 mg / mL to obtain the reference solution.

[0123] Preparation of test solution: Accurately weigh 2.5 g of dressing 1 into a weighing bottle, add water to a quantitative amount of 10 g to obtain the test solution.

[0124] Preparation of blank solution: Accurately weigh 1-2.5 g of the dressing without collagen added into a weighing bottle, and add water to quantify to 10 g to obtain a blank solution.

[0125] 4. Chromatographic conditions

[0126] Stationary phase: chromatographic column (Agilent Eclipse XDB-C18, 4.6×150nm, 5μm); mobile phase: phase A (0.1% (v / v) TFA aqueous solution) and phase B (0.1% (v / v) TFA acetonitrile solution), gradient elution conditions are shown in Table 1; flow rate: 1.0 mL / min; injection volume: 10 μL; column temperature: 30°C; detection wavelength: 214 nm.

[0127] Table 1 Gradient elution program

[0128] Time (min) Phase A (volume fraction / %) Phase B (volume fraction / %) 0 95 5 3 95 5 6 88 12 8 87 13 9 85 15 14 80 20 20 75 25 22 74.5 25.5 27 70 30 29 95 5 30 95 5

[0129] 5. Exclusivity

[0130] Take 10 μL of the reference solution, test solution and blank solution respectively and inject them into the liquid chromatograph, operate according to the chromatographic method and record the chromatogram.

[0131] Results: Chromatogram Figure 1 The reference solution and the test solution have the same chromatographic peak at RT = 21.5min, while the blank solution has no same chromatographic peak at this retention time and no adjacent peaks, indicating that the method has good specificity.

[0132] Acceptable standard (refer to the 2020 edition of the Chinese Pharmacopoeia: 9101 Analytical Method Validation Guidelines): No chromatographic peak appears at the position of the main peak (collagen peak) in the blank solution. If there are adjacent peaks, the separation degree of the adjacent peaks is greater than 1.5.

[0133] 6. Linearity and range

[0134] The concentrations of the reference solution are 0.1 mg / ml, 0.4 mg / ml, 0.6 mg / ml, 0.8 mg / ml, 1.0 mg / ml, and 1.2 mg / ml, respectively. Samples are injected and tested according to the above chromatographic conditions, and the chromatogram is recorded. The standard curve is drawn with the concentration of the reference solution as the abscissa and the peak area (A) as the ordinate.

[0135] Acceptable standard (refer to the 2020 edition of the "Chinese Pharmacopoeia": 9101 Guidelines for Validation of Analytical Methods): The correlation coefficient of the linear regression equation shall not be less than 0.998.

[0136] Result: Linear equation: y = 9114.5x-98.666, R 2 =0.9994. This indicates that the reference solution has a good linear relationship in the concentration range of 0.1-1.2 mg / ml. The results are shown in Table 2 and Figure 2 .

[0137] Table 2 Linearity results

[0138] Concentration (mg / ml) 0.1 0.4 0.6 0.8 1 1.2 Peak area 838.44 3426.6 5422.63 7322.52 8939.87 10827.375

[0139] 7. Repeatability test

[0140] Prepare 6 test sample solutions in parallel, inject and test according to the chromatographic conditions, and record the chromatogram.

[0141] Acceptable standard (refer to the 2020 edition of the "Chinese Pharmacopoeia": 9101 Guidelines for Validation of Analytical Methods): The relative standard deviation (RSD) value is less than 4%.

[0142] Results: As shown in Table 3, the RSD value of the six parallel samples was 1.69%, indicating that the method had good reproducibility.

[0143] Table 3 Repeatability results

[0144]

[0145] 8. Precision test

[0146] Take the test solution, inject 6 times continuously according to the chromatographic conditions, and record the chromatogram. Calculate the content by peak area or according to the linear equation, and then calculate its relative standard deviation (RSD) value.

[0147] Acceptable standard (refer to the 2020 edition of the "Chinese Pharmacopoeia": 9101 Guidelines for Validation of Analytical Methods): RSD value is no more than 4%.

[0148] Results: As shown in Table 4, the RSD value of the same sample after 6 consecutive injections was 3.28%, indicating that the method had good precision.

[0149] Table 4 Precision results

[0150]

[0151] 9. Accuracy (recovery rate) test

[0152] Take 9 portions of the test solution, weigh accurately, and divide them into 3 groups. Add 0.5 ml, 0.625 ml, and 0.75 ml of collagen solution (recombinant type III humanized collagen lyophilized and dissolved in purified water, concentration 4 mg / mL) to each group, inject and detect according to the above-mentioned chromatographic conditions, and record the chromatogram.

[0153] Acceptable standard (refer to the 2020 edition of the "Chinese Pharmacopoeia": 9101 Guidelines for Validation of Analytical Methods): When the content of the component to be tested in the sample is 0.01%, the recovery limit is 85%-110%, and the RSD value is no more than 5%.

[0154] Results: As shown in Table 5, the average recovery rate was 93.40% and the RSD value was 4.2%, indicating that the method had a good recovery rate and was accurate and reliable.

[0155] Table 5 Accuracy results

[0156]

[0157] 10. Limit of Detection (LOD)

[0158] Dilute the reference solution by appropriate multiples, inject the sample according to the method, record the chromatogram, calculate the signal-to-noise ratio (S / N) of the main peak, and the concentration when S / N≈3 is the minimum detection concentration, i.e., the detection limit.

[0159] Results: When the collagen concentration was 0.05 mg / ml, S / N=4. The minimum detection concentration of collagen by this method was 0.05 mg / ml.

[0160] 11. Limit of Quantitation (LOQ)

[0161] Dilute the reference solution by appropriate multiples, inject the sample according to the method, record the chromatogram, calculate the signal-to-noise ratio (S / N) of the main peak, and the concentration when S / N≈10 is the lowest quantitative concentration, i.e., the quantitative limit.

[0162] Results: When the collagen concentration was 0.1 mg / ml, S / N=12. The minimum detection concentration of collagen by this method was 0.1 mg / ml.

[0163] Example 2

[0164] 1. Instrument

[0165] Agilent 1260 high performance liquid chromatograph (UV detector), BCE3202-1CCN electronic balance (Sartorius).

[0166] 2. Reagents and Materials

[0167] Trifluoroacetic acid (Merck, TFA suitable for HPLC, ≥99.0%), acetonitrile (Merck, suitable for HPLC, gradient grade, ≥99.9%), water (Wahaha), sodium hyaluronidase (Merck, H1136-1AMP), dressing 2 (Shanxi Jinbo Biopharmaceutical Co., Ltd.), recombinant type III humanized collagen (Shanxi Jinbo Biopharmaceutical Co., Ltd.), recombinant collagen sterile repair dressing (Shanxi Jinbo Biopharmaceutical Co., Ltd., batch number: 01230501, 01230502, 01230503, 01230601; the concentration of recombinant type III humanized collagen is 0.1 mg / ml);

[0168] Dressing 2 formula: recombinant humanized type III collagen (concentrations are 0, 0.05, 0.1, 0.125, 0.25, 0.5, and 1.0 mg / ml, respectively), supplemented with sodium hyaluronate and PBS buffer solution; the formula and process of Dressing 2 are consistent with that of Dressing 1.

[0169] 3. Solution Preparation

[0170] Preparation of reference solution: Accurately weigh 2-5.0 g of dressings of different concentrations, place them in weighing bottles, add 200 μL of sodium hyaluronate enzyme, shake well, and place at 5°C for full reaction to obtain reference solution.

[0171] Preparation of test solution: Accurately weigh 5.0 g of recombinant collagen sterile repair dressing, put it in a weighing bottle, add 200 μL of sodium hyaluronate enzyme, shake well, and place it at 5°C for full reaction to obtain the test solution.

[0172] Preparation of blank solution: Accurately weigh 25.0 g of the dressing without collagen added into a weighing bottle, add 200 μL of sodium hyaluronate enzyme, and shake well to obtain a blank solution.

[0173] 4. Chromatographic conditions

[0174] Stationary phase: chromatographic column (Agilent Eclipse XDB-C18, 4.6×150nm, 5μm); mobile phase: phase A (0.1% (v / v) TFA aqueous solution) and phase B (0.1% (v / v) TFA acetonitrile solution), gradient elution conditions are shown in Table 1; flow rate: 1.0mL / min; injection volume: 20μL; column temperature: 30℃; detection wavelength: 214nm.

[0175] 5. Exclusivity

[0176] Take 20 μL of blank solution and reference solution respectively and inject them into liquid chromatograph, operate according to the chromatographic method and record the chromatogram.

[0177] Results: Chromatogram Figure 3 The reference solution with a concentration of 0.1mg / ml-1.0mg / ml has a chromatographic peak at RT=20.5min. The reference solution with a concentration of 0.05mg / ml and the blank solution have no identical chromatographic peaks at this retention time, and no adjacent peaks. The reference solution with a concentration of 0.05mg / ml is below the detection limit, so there is no peak at the same position. This indicates that the method has good specificity.

[0178] Acceptable standard (refer to the 2020 edition of the Chinese Pharmacopoeia: 9101 Analytical Method Validation Guidelines): No chromatographic peak appears at the position of the main peak (collagen peak) in the blank solution. If there are adjacent peaks, the separation degree of the adjacent peaks is greater than 1.5.

[0179] 6. Linearity and range

[0180] The concentrations of the reference substances are 0.05 mg / ml, 0.1 mg / ml, 0.125 mg / ml, 0.25 mg / ml, 0.5 mg / ml, and 1.0 mg / ml, respectively. Samples are injected and tested according to the above chromatographic conditions, and the chromatogram is recorded. The standard curve is drawn with the concentration of the reference substance solution as the abscissa and the peak area (A) as the ordinate.

[0181] Acceptable standard (refer to the 2020 edition of the "Chinese Pharmacopoeia": 9101 Guidelines for Validation of Analytical Methods): The correlation coefficient of the linear regression equation shall not be less than 0.998.

[0182] Result: Linear equation: y = 17837x-709.15, R 2 =0.9995. This indicates that the reference solution has a good linear relationship in the concentration range of 0.05-1.0 mg / ml. The results are shown in Table 6 and Figure 4 .

[0183] Table 6 Linearity results

[0184] Concentration (mg / ml) 0.05 0.1 0.125 0.25 0.5 1.0 Peak area 144.53 1029.925 1739.1525 3725.6425 8015.85 17209.3975

[0185] 7. Sample testing

[0186] Prepare 2 test sample solutions in parallel, perform injection testing according to the chromatographic conditions, and record the chromatograms.

[0187] Results: As shown in Table 7, the content of the test sample was in the range of 80%-120%, and its relative standard deviation (RSD) value was 4.69%.

[0188] Table 7 Sample test results

[0189]

[0190] Example 3

[0191] 1. Instrument

[0192] Agilent 1260 high performance liquid chromatograph (ultraviolet detector), BCE3202-1CCN electronic balance (Sartorius), HH.S21-4 electric constant temperature water bath (Shanghai Boxun), PB-30 acidity meter (Sartorius).

[0193] 2. Reagents and Materials

[0194] Trifluoroacetic acid (Merck, TFA suitable for HPLC, ≥99.0%), formic acid (Merck), acetonitrile (Merck, suitable for HPLC, gradient grade, ≥99.9%), water (Wahaha), sodium hyaluronate (Merck, H1136-1AMP), hyaluronidase (Huaxi Biotechnology, 10000IU / ml), sodium hydroxide (AR, Xilong Science), hydrochloric acid (AR, Tianjin Fengchuan), dressing 1 (Shanxi Jinbo Biopharmaceutical Co., Ltd.).

[0195] Preparation of sodium hydroxide solution: Accurately weigh an appropriate amount of sodium hydroxide, dissolve and make up to volume to obtain a 1.0 mol / L sodium hydroxide solution; then measure an appropriate amount and dilute it to a 0.1 mol / L sodium hydroxide solution.

[0196] Preparation of hydrochloric acid solution: Accurately measure an appropriate amount of hydrochloric acid solution and dilute to volume to obtain a 1.0 mol / L hydrochloric acid solution, then measure an appropriate amount to dilute to a 0.1 mol / L hydrochloric acid solution.

[0197] Dressing 1 formula: recombinant humanized type III collagen (concentration of 1.0 mg / ml), supplemented with sodium hyaluronate and PBS buffer solution.

[0198] 3. Investigation of sample pretreatment methods

[0199] Currently, there is no literature on the determination of collagen content in dressings and complete sample pretreatment methods. This experiment investigated the pretreatment of samples by adding different concentrations of alkali, acid, heating, and enzymes.

[0200] The samples under different treatment conditions were subjected to chromatographic detection (chromatographic conditions were the same as those in Example 1), and it was found that high concentrations of alkali and acid (concentration of 1.0 mol / L) would destroy the viscosity of the dressing and make it thinner. At the same time, the change of adding acid was not as good as that of adding alkali. The dressing still had a little viscosity, but the damage to the protein was relatively large (such as Figure 5 , the peak area was found to be reduced by comparison). Although low concentrations of alkali and acid (concentration of 0.1 mol / L) destroyed less protein, the sample viscosity was high. After dilution, the content was lower than the detection limit and the content could not be accurately measured. At the same time, the sample was placed in a water bath at 60°C, and it was found that the protein would be denatured without heating and the viscosity of the dressing could not be destroyed. Therefore, the dilution method was used for pretreatment of dressings with high protein content.

[0201] By diluting the dressing at different times, it was found that after diluting the dressing 4 times, the viscosity decreased, and the protein content could be detected after diluting it 4 times. When the dilution ratio was less than 3, the dressing sample was viscous and difficult to pass through the 0.22μm filter membrane; when the dilution ratio was higher than 4, the content would decrease, which would affect the test results.

[0202] For dressings with low protein concentration, enzymatic hydrolysis can be used. Enzymes are specific, and sodium hyaluronate enzyme is an enzyme that can hydrolyze hyaluronic acid, thereby reducing the viscosity of the dressing.

[0203] In the early stage, 90 μL of hyaluronidase (Huaxi Biotechnology, 10000 IU / ml) was added to 1g of dressing. It was found that 90 μL of enzyme would quickly destroy the viscosity of the dressing during the enzymatic hydrolysis process, but it would also destroy collagen (such as Figure 6 ), so the enzyme amount was reduced to 50μL, 20μL, and 10μL, and the effect of different enzyme amounts on the protein content of the dressing was investigated. It was found that 50μL and 20μL enzymes could quickly destroy the dressing viscosity after adding for 5 minutes, while 10μL enzyme destroyed the dressing viscosity more slowly. At the same time, the protein content of the dressings with different enzyme amounts was detected, and it was found that the peak area of ​​the dressing was close (such as Figure 7 ), but no peak was detected after the sample reacted for 12 hours. The longer the reaction time, the more the protein will be degraded under the action of the enzyme. The analysis results show that the enzyme activity is relatively large and has a greater impact on the protein content.

[0204] Later, another hyaluronidase (Merck, 1amp, 100IU / ml) was added to 5g of dressing to investigate the effect of different enzyme amounts of 50μL, 100μL, 200μL, and 250μL on the protein content of the dressing. It was found that after 12h of adding 50μL of enzyme to the sample, there was still viscosity, while the sample had become liquid under other enzyme amounts. The protein content under different enzyme amounts and different reaction times was detected in the liquid phase, and the results (e.g. Figures 8 to 10 ) found that when 200μL enzyme entered the liquid phase after 12h and 24h of reaction, the protein peak areas of the two were basically the same. The sample entered the liquid phase after 2h of reaction, and its peak area was greater than half of that at 12h, indicating that sodium hyaluronate had been completely degraded after 12h of reaction with the enzyme in the dressing, and the long reaction time had no effect on the protein. When 100μL enzyme entered the liquid phase after 24h of reaction, the protein peak area was close to that of 200μL enzyme. When 250μL enzyme entered the liquid phase after 12h of reaction, the protein peak area was basically the same as that of 200μL enzyme, indicating that the enzyme can be used to detect low-concentration protein dressings with 200μL of enzyme.

[0205] 4. Selection of chromatographic conditions

[0206] (1) Selected instruments and materials

[0207] UV spectrophotometer (Mepda, p7), Agilent 1260 high performance liquid chromatograph (UV detector), BCE3202-1CCN electronic balance (Sartorius), trifluoroacetic acid (Merck, TFA suitable for HPLC, ≥99.0%).

[0208] (2) Detection wavelength selection

[0209] After the dressing was diluted, a full wavelength scan was performed in the ultraviolet range of 200-800nm, and it was found that there was a maximum characteristic absorption at 214nm, so the detection wavelength was set to 214nm (see Fig.11 ).

[0210] (3) Column selection

[0211] Agilent ZORBAX Eclipse XDB columns have good stability in a wide pH range of 6-9, and can use low concentration buffers of 0.01-0.02M to obtain the highest column stability.

[0212] (4) Selection of mobile phase (Except for the mobile phase, other experimental conditions are the same as those in Example 1)

[0213] Trifluoroacetic acid is used as an ion pair reagent. The trifluoroacetic acid in the mobile phase interacts with the hydrophobic bonded phase and the residual polar surface in multiple modes to improve the peak shape and overcome the peak broadening and tailing problems. Fig.12 As shown, the maximum UV absorption peak of trifluoroacetic acid is below 200nm, which has little interference with the detection of protein at 214nm. The concentration of trifluoroacetic acid added to the mobile phase is 0.1% (v / v). At this concentration, most reversed-phase columns can produce good peak shapes. When the concentration of trifluoroacetic acid is much lower than this level, the peak broadening and tailing become very obvious, so 0.1% (v / v) trifluoroacetic acid is selected as the mobile phase.

[0214] (5) Selection of column temperature and flow rate (except column temperature and flow rate, other experimental conditions are the same as those in Example 1)

[0215] Based on the previous research, the peak separation effects were compared under the conditions of 30℃ and 35℃ column temperature and 1.0ml / min, 0.8ml / min, and 0.6ml / min flow rates. The results are as follows Fig.13 As shown, it shows that under this method, 30℃ column temperature and 1.0ml / min flow rate are more conducive to the separation of collagen peak.

[0216] Example 4

[0217] Kjeldahl nitrogen determination method:

[0218] Principle: After nitrogen-containing organic matter is digested with sulfuric acid, the generated ammonium sulfate is decomposed by sodium hydroxide to release ammonia, which is distilled into boric acid solution with the help of water vapor to form ammonium borate, which is finally titrated with strong acid. The nitrogen content of the test sample can be calculated based on the strong acid consumption.

[0219] Reagents: nitrogen determination catalyst tablets (potassium sulfate and copper sulfate mixed tablets), sulfuric acid, 40wt% sodium hydroxide, 2wt% boric acid, dilution water (ultrapure water), 0.1mol / L sulfuric acid, dressing 3 (Shanxi Jinbo Biotechnology Co., Ltd.).

[0220] Instruments: graphite digester, fully automatic Kjeldahl nitrogen analyzer.

[0221] Dressing 3 formula: recombinant humanized type III collagen (concentrations are 0.1, 0.5, and 1.0 mg / ml, respectively), supplemented with sodium hyaluronate and PBS buffer solution; the formula and process of Dressing 3 are consistent with those of Dressing 2 and Dressing 1.

[0222] step:

[0223] (1) Weigh 5.0 g of dressing (dressing 3) and place it in a digestive tube. Add appropriate amounts of potassium sulfate and copper sulfate mixed tablets and sulfuric acid in sequence. Place the digestive tube in a digestion instrument and begin digestion according to the instructions in the instrument until the solution turns clear green. Remove the tube and cool it.

[0224] (2) Place the prepared alkali solution (40 wt% sodium hydroxide), absorption solution (2 wt% boric acid) and appropriate titration solution (0.1 mol / L sulfuric acid) in the corresponding bottles of the automatic distiller, install the digestive tube in the correct position according to the requirements of the instrument manual, close the safety door, and connect the water source.

[0225] (3) Add 1 / 3 of water to the digestion tube and clean the pipeline. First, change to acid cleaning, then clean the alkaline pipeline, clean the boric acid pipeline, and finally clean the receiving cup.

[0226] (4) Change the water, add 1 / 3 of water to the digestion tube, test the pipeline, clean the internal pipeline, and start automatic distillation and titration.

[0227] (5) Dressing test

[0228] The results are shown in Table 8 below:

[0229] Table 8 Kjeldahl nitrogen determination test results

[0230] Protein concentration in dressing Parallel 1 Parallel 2 Parallel 3 0.01%(0.1mg / mL) 0.0000% 0.0000% 0.0079% 0.05%(0.5mg / mL) 0.0509% 0.0544% 0.0511% 0.1%(1.0mg / mL) 0.1085% 0.1037% 0.1144%

[0231] in conclusion:

[0232] ① The protein contents of three groups of parallel dressings at 0.1 mg / ml were 0.0000%, 0.0000%, and 0.0079%, which were significantly different from the theoretical protein content (0.01%). Moreover, the data were not parallel and had poor repeatability.

[0233] ② The protein content of three groups of parallel dressings with 0.5 mg / ml was measured to be 0.0509%, 0.0544% and 0.0511%, which was basically consistent with the theoretical protein content (0.05%), with a slight error between the data.

[0234] ③ The protein contents of three groups of parallel dressings with 1.0 mg / ml were measured to be 0.1085%, 0.1037% and 0.1144%, which were basically consistent with the theoretical protein content (0.1%), but there were errors between the data.

[0235] Use the method in Example 1 or 2 of the present invention:

[0236] ① The dressing was pre-treated by enzymatic hydrolysis (Example 2), and the chromatogram was as follows: Fig.14A As shown, the protein contents of two groups of parallel samples at 0.1 mg / ml were measured to be 0.0998 mg / ml and 0.0993 mg / ml, which were basically consistent with the theoretical protein content, with a slight error between the data.

[0237] ② The dressing was pre-treated by enzymatic hydrolysis (Example 2), and the chromatogram was as follows: Fig. 14B As shown, the protein contents of two groups of parallel samples at 0.5 mg / ml were measured to be 0.5001 mg / ml and 0.5010 mg / ml, which were basically consistent with the theoretical protein content, with a slight error between the data.

[0238] ③ The dressing was pre-treated using the dilution method (Example 1), and the chromatogram was as follows: Fig. 14C As shown, the protein contents of two groups of parallel samples at 1.0 mg / ml were measured to be 0.9968 mg / ml and 0.9911 mg / ml, which were basically consistent with the theoretical protein content, with a slight error between the data.

[0239] In summary, the present invention establishes a method for detecting the collagen content in dressings based on high performance liquid chromatography. The method has simple pretreatment, fast analysis, high accuracy and good precision, and can be used for the determination of the collagen content in dressings.

Claims

1. A method for detecting the content of recombinant humanized collagen in a sample, characterized in that: The sample contains recombinant humanized collagen and sodium hyaluronate; The method comprises the following steps: preparation of reference solution, preparation of test solution, liquid chromatography detection and data analysis; When the content of recombinant humanized collagen in the sample is greater than or equal to 0.5 mg / mL, the preparation of the test solution includes the steps shown in the following dilution method: Dilution method: accurately weigh the sample, place it in a container, add purified water or PBS solution to dilute it 3 to 4 times; When the content of recombinant humanized collagen in the sample is less than or equal to 1.0 mg / mL, the preparation of the test solution includes the steps shown in the following enzymatic hydrolysis method: Enzymatic method: accurately weigh the sample, place it in a container, add hyaluronidase, mix well, and place it at 4-6℃ for enzymatic reaction to obtain the product; The conditions used in the liquid chromatography detection include: The chromatographic column is an octadecylsilane bonded silica gel chromatographic column; The mobile phase is a water-acetonitrile binary mobile phase system, in which mobile phase A is a trifluoroacetic acid aqueous solution with a trifluoroacetic acid content of 0.1% v / v, and mobile phase B is a trifluoroacetic acid acetonitrile solution with a trifluoroacetic acid content of 0.1% v / v; The elution method is gradient elution, and the procedure of the gradient elution is as follows:

2. The method according to claim 1, characterized in that The data analysis includes calculating the concentration of the recombinant humanized collagen in the test solution by using an external standard method, and then obtaining the content of the recombinant humanized collagen in the sample.

3. The method according to claim 1, characterized in that When the preparation of the test solution includes the steps shown in the dilution method, the preparation of the reference solution includes the following steps: accurately weigh the recombinant humanized collagen reference, place it in a container, and add a solvent to dissolve it.

4. The method according to claim 3, characterized in that The solvent is purified water or PBS solution.

5. The method according to claim 1, characterized in that When the preparation of the test solution includes the steps shown in the enzymatic hydrolysis method, the preparation of the reference solution includes the following steps: accurately weighing a dressing reference, placing it in a container, adding hyaluronidase, mixing, and placing it in an environment of 4 to 6°C for enzymatic hydrolysis reaction to obtain; wherein, the dressing reference contains the recombinant humanized collagen and sodium hyaluronate.

6. The method according to claim 1 or 5, characterized in that: The mass ratio of the amount of the hyaluronidase to the sample is (1-900) IU: 1 g, and the time of the enzymatic reaction is 5 min to 24 h.

7. The method according to claim 1, characterized in that The conditions adopted by the liquid chromatography detection also include: Flow rate: 0.5-1.3 mL / min; Column temperature is 27-37°C; The detection wavelength is 200-230nm; The injection volume was 8-22 μL.